RESULTS
Patients admitted to Hospital Moinhos de Vento (HMV), from March 15 to
July 31, 2020, were included in the study, a total of 459 individuals
with a median age of 60.0 years (IQR, 45.0 to 72.0), being 57.1% males.
Hypertension (46.8%), pulmonary disease (emphysema, COPD or asthma)
(22.1%) and diabetes (21.6%); fever (63.5%), cough (60.6%) and
dyspnea (38.7) were the frequently reported comorbidities and symptoms
at hospital admission. The median onset of symptoms before admission was
7.0 days (IQR, 4.0 to 9.5); 136 (29.6%) patients needed admission to
the ICU and 97 (21.1%) required MV. The mean length of stay in
hospital, MV and ICU was 13.9 (SD±16.1), 20.1 (SD±15.6) and 21.2
(SD±18.4) days, respectively.
Regarding pharmacologic therapies, HCQ-AZM was administered to 105
(23.2%) patients; HCQ-corticosteroid to 49 (10.7%) and
AZM-corticosteroid to 212 (46.8%). Therapeutic anticoagulation was
administered to 138 (31.8%) patients, being 36 (7.9%) combined with
HCQ and 78 (17.2%) with AZM-Corticosteroid. The combination of
HCQ-AZM-Corticosteroid and therapeutic anticoagulation occurred in 21
patients (4.6%). For patients treated with AZM-Corticosteroid the risk
for ICU admission 0.17 (OR; 95% CI 0.05 to 0.57), for MV 0.16 (OR;
95%CI 0.04 to 0.74) and mortality was 0.16 (OR; 95% CI 0.03 to 0.91).
For those patients treated with HCQ-AZM-Corticosteroid, the association
represented loss of benefit (Figure 1).
Figure 1 Outcomes risk according to treatment combined